The prevalence of Parkinson's disease in Europe is experiencing an alarming rise, with significant financial consequences for healthcare systems. In 2019, approximately 2.2 million people were affected in 47 countries, leading to direct costs of over 17 billion euros. The increase in cases, nearly doubled since 1990, is linked to the aging population and better diagnostic methods.